Intraoperative tranexamic acid to decrease blood loss during myomectomy: a randomized, double-blind,...

Area of Science:

• Gynecologic Surgery
• Surgical Hemorrhage Control
• Pharmacology

Background:

• Myomectomy carries a substantial risk of hemorrhage.
• Tranexamic acid (TXA) is an antifibrinolytic agent used to reduce surgical bleeding.
• Its effectiveness in gynecologic surgery, specifically myomectomy, is not well-established.

Purpose of the Study:

• To evaluate the impact of early intravenous tranexamic acid administration on perioperative bleeding.
• To assess the effect of TXA on blood transfusion requirements in women undergoing myomectomy.
• To investigate TXA's utility in minimizing blood loss during myomectomy procedures.

Main Methods:

• A double-blinded, randomized, placebo-controlled trial was conducted.
• Participants included women at risk for significant blood loss during myomectomy.
• Patients received either intravenous tranexamic acid or saline placebo before surgery.

Main Results:

• No significant difference in median estimated blood loss between TXA and placebo groups (200 mL vs. 240 mL).
• No difference in surgical duration or change in hemoglobin levels.
• While no patients in the TXA group required transfusion, 13.3% in the placebo group did (P=.11).

Conclusions:

• Early intravenous tranexamic acid administration did not decrease blood loss in patients undergoing myomectomy.
• The study found no significant benefit of TXA in reducing perioperative bleeding or transfusion rates.
• Further research may be needed to explore TXA's role in specific gynecologic surgical contexts.